1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Taiko Pharmaceutical Co., Ltd.

Taiko Pharmaceutical Co., Ltd.

TTSE:4574
262.00
JPY
-2.00
(-0.76%)
14.24BMarket Cap
Nov 13Next Earn
Taiko Pharmaceutical Co., Ltd.
TSE:4574
(Tokyo Stock Exchange)

Recent

price

262.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2020
2021
2022
2023
2024
2025
TTM
JPY
116.07
172.21
193.72
255.95
241.64
214.7
201.2
222.36
241.93
350.46
409.46
246.39
115.59
129.22
125.38
127.34
- -
Revenue per Share
-57.85
12.41
27.1
45.32
46.31
21.74
25.48
25.8
33
57.57
89.18
-220.51
-112.26
-76.25
17.89
18.37
- -
Basic EPS, GAAP
-49.03
9.1
23.01
85.22
-57.51
-87.45
62.54
-4.66
28.97
76.8
-86.65
-73.43
-47.66
-8.89
3.49
10.15
- -
Free Cash Flow per Basic Share
3.27
1.61
5.07
4.94
8.49
8.28
4.75
6.66
11.62
11.71
19.58
17.97
- -
0.02
0.02
- -
- -
Dividend per Share
216.19
225.5
249.16
292.5
325.31
336.17
363.17
384.42
406.33
451.27
525.93
293.82
184.57
134.9
158.65
169.51
167.47
Book Value per Share
214.17
223.97
248.05
291.61
324.48
334.94
362.05
382.26
400.81
446.14
518.56
286.96
179.48
134.88
158.11
168.83
166.75
Tangible Book Value per Share
39
39
38
39
38
39
41
42
43
43
43
44
44
47
50
50
50
Basic Weighted Avg Shares
4,470
6,691
7,416
9,868
9,238
8,295
8,285
9,438
10,378
14,936
17,684
10,720
5,040
6,120
6,292
6,397
- -
Sales/Revenue/Turnover
-27.8
7.7
15.12
26.25
27.7
16.25
18.65
19.68
19.56
25.61
31.96
-46.16
-61.09
-16.44
10.01
7.18
- -
Operating Margin (%)
241
259
251
259
281
351
445
454
461
495
473
941
737
704
256
265
- -
Depreciation Expense
-2,228
482
1,038
1,747
1,771
840
1,049
1,095
1,415
2,453
3,852
-9,594
-4,895
-3,611
898
923
- -
Net Income, GAAP
- -
- -
5.73
31.58
35.82
29.49
29.62
29.48
28.73
29.99
28.33
- -
- -
- -
- -
3.55
- -
Effective Tax Rate (%)
-49.84
7.21
13.99
17.71
19.17
10.13
12.67
11.6
13.64
16.43
21.78
-89.5
-97.12
-59
14.27
14.43
- -
Profit Margin (%)
5,390
6,307
6,972
8,754
5,475
5,425
8,039
8,748
9,746
11,790
12,334
9,463
4,763
6,063
5,906
5,924
5,794
Working Capital
37
22
12
28
36
28
19
15
39
52
64
3,814
2,741
2,021
803
10
- -
LT Debt
8,293
8,784
9,479
11,406
12,473
13,140
15,385
16,420
17,485
19,374
22,781
12,805
8,043
6,738
7,963
8,518
8,425
Total Equity
- -
- -
11.47
16.16
12.89
7.15
7.45
8.04
8.32
13.96
18.25
- -
- -
- -
- -
4.5
- -
Return on Invested Capital (%)
- -
- -
11.32
16.68
14.77
6.55
7.34
6.87
8.33
13.27
18.2
- -
- -
- -
- -
9.44
- -
Return on Capital (%)
-23.57
5.65
11.36
16.73
14.83
6.56
7.36
6.89
8.35
13.31
18.27
-53.92
-46.96
-48.86
12.22
11.2
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
1,276
- -
235
LT Borrowings
1,326
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
50
50
50
Market Capitalization
20,881
14,824
14,237

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
8,795
- -
7,198
Cash, Cash Equivalents & STI
5,152
- -
3,166
Accounts Receivable, Net
1,815
- -
1,934
Inventories
1,609
- -
1,904
Total Current Liabilities
2,437
- -
1,404
Payables & Accruals
- -
- -
- -
ST Debt
1,276
- -
235
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1.34%
-14.41%
6.97%
Free Cash Flow
-114.26%
-15.89%
191.43%
Net Income, GAAP
-35.76%
-109.28%
2.78%
Sales/Revenue/Turnover
1.96%
-13.29%
1.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,377
1,483
- -
- -
6,292
2025
- -
- -
- -
- -
6,397
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9.41
5.82
- -
- -
17.89
2025
- -
- -
- -
- -
18.37
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.02
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Taiko Pharmaceutical Co., Ltd. (4574.T) manufactures and sells over-the-counter (OTC) medicines and infection control products primarily in Japan and select international markets. The company operates through three main segments: Pharmaceutical, which centers on its flagship gastrointestinal medications including Seirogan tablets and Seirogan Toi-A for treating loose stools, diarrhea, vomiting, food and water poisoning symptoms, and toothache; Infection Control, featuring a leading brand of airborne disinfectants and related quasi-drugs for regulating intestinal movements, relieving stomach distention, loose stools, and constipation; and Others, encompassing supplementary health-related offerings. Founded in 1946 and headquartered in Suita City, Osaka, Japan, Taiko Pharmaceutical exports its products to markets including Hong Kong and Taiwan, targeting consumers seeking self-medication solutions for digestive and infectious issues. With approximately 214 employees, the company maintains a focus on research and development to sustain its over 100-year legacy in gastrointestinal remedies like Seirogan, first introduced generations ago. In recent developments, Taiko Pharmaceutical booked extraordinary gains of 142 million yen from a subsidiary liquidation, contributing to revised earnings forecasts for fiscal year 2025 while navigating a challenging period marked by a 7.6% decline in net sales and 55.3% drop in operating profit for the first nine months of 2025. The company continues its prior business alliance with Earth Corporation for joint product development using chlorine dioxide technology, even after Earth sold its 5.50% stake in 2022. Additionally, strategic investments from Kingworld Medicines Group, which increased its holdings to approximately 6.42% of Taiko's shares by mid-2023 through multiple subscriptions, bolster upstream supply chain collaborations and distribution for products like Seirogan in China.